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Summary
Background Even though progress has been made, the detection of melanoma still
poses a challenge. In light of this situation, the Nevisense electrical impedance
spectroscopy (EIS) system (SciBase AB, Stockholm, Sweden) was designed and
shown to have the potential to be used as an adjunct diagnostic tool for mela-
noma detection.
Objectives To assess the effectiveness and safety of the Nevisense system in the dis-
tinction of benign lesions of the skin from melanoma with electrical impedance
spectroscopy.
Methods This multicentre, prospective, and blinded clinical study was conducted
at five American and 17 European investigational sites. All eligible skin lesions in
the study were examined with the EIS-based Nevisense system, photographed,
removed by excisional biopsy and subjected to histopathological evaluation. A
postprocedure clinical follow-up was conducted at 7  3 days from the initial
measurement. A total of 1951 patients with 2416 lesions were enrolled into the
study; 1943 lesions were eligible and evaluable for the primary efficacy end
point, including 265 melanomas – 112 in situ and 153 invasive melanomas with
a median Breslow thickness of 057 mm [48 basal cell carcinomas (BCCs) and
seven squamous cell carcinomas (SCCs)].
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Results The observed sensitivity of Nevisense was 966% (256 of 265 melanomas)
with an exact one-sided 95% lower confidence bound estimated at 942% and an
observed specificity of 344%, and an exact two-sided 95% confidence bound esti-
mated at 320–369%. The positive and negative predictive values of Nevisense
were 211% and 982%, respectively. The observed sensitivity for nonmelanoma
skin cancer was 100% (55 of 48 BCCs and seven SCCs) with an exact two-sided
95% confidence bound estimated at 935–1000%.
Conclusions Nevisense is an accurate and safe device to support clinicians in the
detection of cutaneous melanoma.
What’s already known about this topic?
• Although progress has been made in the detection of melanoma it still poses a
challenge.
• Electrical impedance spectroscopy (EIS) may potentially be used as a diagnostic aid
for the detection of melanoma.
What does this study add?
• In the largest international prospective study of its kind in melanoma detection,
the EIS system Nevisense was shown to be both accurate and safe in the lesion
cohort studied.
• In the absence of a perfect gold standard, the accuracy of a device should be com-
pared with the consensus diagnosis from multiple experts.
Early detection of melanoma is vital for treatment outcome
and survival. Treatment of early-stage melanoma is mostly
curative, whereas thicker melanomas are associated with a
poor 5-year survival rate due to increased metastatic poten-
tial.1,2 In most instances, physicians feel fairly confident when
distinguishing nonsuspicious from suspicious lesions by rely-
ing on unaided eye examination, dermoscopy assessment and
patient history. However, cutaneous melanomas can be misdi-
agnosed as benign, and a significant proportion of benign
lesions are unnecessarily excised. The sensitivity of the clinical
diagnosis of cutaneous melanoma with unaided eye examina-
tion is around 60% and can improve significantly with the use
of dermoscopy.3–37 Although progress has been made in the
detection of melanoma it still poses a challenge, especially in
its earlier stages. Therefore, a number of technologies utilizing
either visual or nonvisual techniques, such as total body pho-
tography,38,39 confocal microscopy,40,41 Raman spectros-
copy,42,43 multispectral imaging,44 automated dermoscopy
image analysis,45 genomic detection of melanoma by stratum
corneum stripping46 and electrical impedance spectroscopy
(EIS),47,48 have been developed to support physicians in
detecting melanomas at an earlier stage. In a previous study,
the EIS-based Nevisense system (SciBase AB, Stockholm, Swe-
den) was shown to have the potential to be used as an adjunct
diagnostic tool, although it was concluded that more clinical
data were necessary to ensure the safety and effectiveness of
the system.48
The aim of this clinical investigation was to assess the safety
and effectiveness of the Nevisense system, which has been
designed to aid in the discrimination between benign lesions
and primary cutaneous melanoma. In this article, results are
presented and discussed in the context of clinical utility.
Materials and methods
Ethical conduct
The guidelines of the revised Declaration of Helsinki, the
Guidelines of Good Clinical Practice (ISO-14155), and the
demands of national and data protection laws and other appli-
cable regulatory requirements were followed. The clinical trial
registration number is NCT01077050 (www.ClinicalTrials.
gov).
Study design and data acquisition
Recruitment into this blinded multicentre prospective study
was conducted at five American and 17 European investiga-
tional sites (Sweden, Germany, Austria, Hungary, U.K. and
Spain). Potential study participants were screened according to
the inclusion and exclusion criteria. Subsequent to written
informed consent, patients were asked about their medical his-
tory and a clinical evaluation was performed. A photograph
and dermoscopic image of each included lesion was taken
© 2014 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
British Journal of Dermatology (2014) 171, pp1099–1107
1100 The Nevisense system in cutaneous melanoma detection, J. Malvehy et al.
before and after Nevisense measurements to document evalua-
tion according to the protocol. In accordance with standard
clinical practice, eligible and evaluable lesions were excised
and subjected to the investigational site’s histopathology evalu-
ation and managed accordingly.
A further histopathological evaluation was completed by a
panel of three experienced histopathologists who evaluated
each lesion independently and were blinded from the investi-
gational site’s original histopathology diagnosis. In the case of
agreement among the experts, the diagnosis was considered as
the study’s histopathological gold standard (HGS). If there was
significant disagreement among the pathology reviewers on
whether the lesion represented a malignancy, the respective
slides were submitted to two additional experts whose diagno-
sis was then chosen as the HGS if they reached agreement. In
case of disagreement by the two additional reviewers, the
corresponding lesion was excluded from the efficacy analysis.
A postprocedure follow-up either by a telephone call or at a
participant’s visit to the investigational site was conducted at
7  3 days after the Nevisense evaluation, at which time the
patient was evaluated for any adverse events.
Inclusion and exclusion criteria
Patients with skin lesions selected for total excision to rule out
melanoma were asked to participate in the study. To minimize
selection bias, all lesions destined for excision were eligible
for inclusion in the study. To ensure a broad spectrum of
excised lesions, dermatologists were encouraged to enroll a
mix of lesions with an even distribution of low-, medium-
and high-risk lesions. The exclusion criteria were derived from
previous studies conducted with the investigational device and
are listed in Table 1.47,48
Review of images
The photographs and dermoscopic images were taken with a
Sony DSC-W290 (Sony, Tokyo, Japan) and a hand-held der-
moscope (DermLite II PRO HR, 3Gen; DermLite, San Juan
Capistrano, CA, U.S.A.). The images were reviewed by three
dermatologists with 2–5 years of experience in dermoscopy
assessment. The option to reach out to additional experienced
dermoscopists in difficult cases was allowed. Lesions were
classified according to the clinical ABCD rule,49,50 the dermo-
scopic ABCD rule,51 the seven-point checklist52 and the overall
suspicion of malignancy classified by the visual classification
board from 0 (benign) to 10 (malignant). This was conducted
to ascertain a standardized clinical and dermoscopic classifica-
tion of the degree of suspicion of malignancy of each study
lesion.
Blinding
The case report forms, the Nevisense measurements and the
histopathological reports were kept blinded from the sponsor
by a contract research organization until classification of all
lesions in the pivotal study had been made.
The investigators were blinded to the entire diagnostic
information of the device to ensure that the device could not
bias the clinical judgement nor affect the clinical management
of the patient in any way.
Electrical impedance spectroscopy measurements
Electrical impedance was measured with the Nevisense system
equipped with a spring-loaded probe and a disposable electrode
having an active area of approximately 5 9 5 mm2. Prior to
measurement, the skin was moistened for 30 s with physiologi-
cal saline solution, after which a reference measurement of
healthy skin close to the lesion was performed. The procedure
was then repeated on the lesion under study. The system
measures the overall electrical resistance and reactance at 35 dif-
ferent frequencies logarithmically distributed between 10 kHz
and 25 MHz at four depth settings with a total of 10 permuta-
tions. The applied voltage and resulting current is limited to
150 mV and 75 lA, respectively, and is not sensed by the
patient. Measurements take approximately 8 s, and within sec-
onds the system computes both a score (0–10) and a dichoto-
mous output (EIS negative/positive) at a fixed cut-off. The fixed
threshold is set at 4, i.e. scores < 4 are EIS negative and scores
of ≥ 4 are EIS positive. The dichotomous output was used in the
study to demonstrate the sensitivity and specificity end points.
Study objective and end point
The objective of this clinical investigation was to determine
the safety and effectiveness of the Nevisense device, which has
been designed to help distinguish between cutaneous mela-
noma and benign lesions of the skin, using EIS relative to the
HGS.
Table 1 Exclusion criteria
Men or women of any ethnic group aged < 18 years
Patient not willing or able to read, understand and sign the
study-specific informed consent form
Metastases or recurrent lesions
Lesion < 2 mm or > 20 mm in diameter
Lesion located on acral skin, e.g. sole or palm
Lesion located on areas of scars, crusts, psoriasis, eczema or
similar skin conditions
Lesion on hair-covered areas, e.g. scalp, beards, moustaches
or whiskers
Lesion located on genitalia
Lesion located in an area that has been previously biopsied or
subjected to any kind of surgical intervention or trauma
Lesion located on mucosal surfaces
Lesion with foreign matter, e.g. tattoo or splinter
Lesion and/or reference located on acute sunburn
Skin surface not measurable, e.g. lesion on a stalk
Skin surface not accessible, e.g. inside ears, under nails
Skin not intact (measurement area), e.g. bleeding or with
clinical noticeable ulceration
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This study had two coprimary analyses, aiming to demon-
strate the accuracy of the Nevisense device: (i) a one-sided
exact 95% confidence bound of the sensitivity in detecting
cutaneous melanoma of > 90% (sensitivity ≥ 090 to detect
melanoma); (ii) nonrandom result at the given sensitivity, i.e.
sensitivity + specificity > 10.
The safety of the Nevisense analysis was measured by the
occurrence and incidence of all adverse events reported for
study participants throughout their participation in the study.
The primary safety end point was achieved if no serious
adverse events related to the device had occurred.
Additional analysis
Clinical histopathological gold standard
To estimate the sensitivity and specificity of the clinical HGS
used for treatment the investigational site’s histopathological
diagnoses were compared with the study HGS. The analysis
was conducted on eligible and evaluable lesions.
Unaided lesion evaluation and dermoscopy assessment
The observed sensitivity and specificity of the visual reference
standard was calculated using the cut-offs prespecified from
literature and the outcome of the different visual classification
algorithms.
Results
Study participants and skin lesions
A total of 1951 participants with 2416 lesions were recruited
between March 2010 and November 2011. The demographic
characteristics of the study population are presented in
Table 2. The median age of the patients was 48 years (range
18–91). Women comprised 519% of the study group. Most
(971%) patients were white and the majority were either of
Fitzpatrick skin type 2 or 3. No significant differences in the
demographic characteristics between the enrolled and the
eligible lesions were observed.
Table 3 presents the distribution of reasons for exclusion
from the effectiveness analysis. Out of the 2416 registered
lesions a total of 473 were excluded, mainly owing to investi-
gator oversight or the inability to render a final histopatholog-
ical diagnosis. Approximately one-quarter of the excluded
lesions were device-related (inadequate reference measurement
quality or general device failures).
Performance of Nevisense
The dichotomous outcome of the Nevisense system was com-
pared with the HGS. Of the 1943 eligible and evaluable
lesions (Table 4), 265 (132%) were cutaneous melanoma, 55
(28%) were nonmelanoma skin cancer (NMSC), including
basal cell carcinomas (BCCs) and squamous cell carcinomas
(SCCs), of which Nevisense correctly identified 256 melano-
mas and all 55 NMSCs, yielding an observed sensitivity of
966% and 1000%, respectively. A total of 157 naevi with
severe dysplasia were included, of which Nevisense gave a
positive reading for malignancy in 132 cases. Seven out of
eight actinic keratoses gave a positive reading. One Merkel cell
carcinoma was included, which was correctly identified as
malignant. Out of the remaining 1457 lesions, 501 were diag-
nosed as negative, yielding an observed specificity of 344%.
No significant difference in the presented sensitivity and speci-
ficity was encountered, when the possible dependency in out-
come between the lesions of the same patient was accounted
for through a generalized linear mixed model. The positive
predictive value (PPV) of Nevisense was 211% and the nega-
tive predictive value (NPV) was 982%. The Nevisense score
was compared with lesion severity and, as can be discerned
from Figure 1, a clear step function is evident for the score
outcome with increasing lesion severity.
Table 2 Demographic characteristics of the enrolled and eligible
participants
Characteristics
Patients enrolled
(n = 1950)
Patients with
eligible lesions
(n = 1611)
Sex
Male 929 (476) 765 (475)
Female 1013 (519) 846 (525)
Missing 8 (04) 0 (0)
Age (years),
median (range)
48 (18–91) 48 (18–91)
Race and ethnicity
Asian 5 (03) 5 (03)
White 1893 (971) 1571 (975)
Black or African
American
2 (01) 2 (01)
Hispanic or Latino 29 (15) 25 (16)
Other 12 (06) 8 (05)
Missing 9 (05) 0 (0)
Fitzpatrick skin type
1. Always burns
easily; never tans
136 (7) 117 (73)
2. Always burns
easily; tans minimally
945 (485) 783 (486)
3. Burns moderately;
tans gradually
635 (326) 526 (327)
4. Burns minimally;
always tans well
192 (98) 158 (98)
5. Rarely burns;
tans profusely
29 (15) 23 (14)
6. Never burns;
deeply pigmented
1 (01) 1 (01)
Missing 12 (06) 3 (02)
Data presented as number (percentage) of patients, except for
age. For one subject, the signed informed consent form could
not be located at the site and the data were thus deleted.
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Nevisense false negatives
Of the nine melanomas classified by Nevisense as false nega-
tive, seven had sufficient image quality to render an outcome
for the ABCD dermoscopy rule and seven-point checklist by
the reviewing dermatologists. The overall visual malignancy
grading scored two of this subset of seven melanomas as
positive with a score of 4, and five as negative with a score of
0–2.
Three of the nine FN lesions were identified on patients
aged < 30 years. The median diameter of these nine lesions
was 4 mm (range 2–8), of which five had a diameter
< 6 mm. Seven were in situ and two were early invasive
melanomas (T1a) with Breslow thicknesses of 04 mm and
06 mm, respectively. The lesions were located on the follow-
ing anatomical locations: lower extremities (n = 4), upper
extremities (n = 1), upper back (n = 2), buttocks (n = 1) and
facial area (n = 1).
Performance of the unaided examination and dermoscopy
assessment
To determine the diagnostic uncertainty of the study lesions, a
postexcisional performance study of unaided examination and
dermoscopy was completed. Of the 1943 eligible and evalu-
able lesions, 1701 (238 melanomas) had sufficient image
Table 3 Reasons for exclusion of lesions from the analysis
Reason for exclusion
No. of
lesions
Sourcen %
Lesions included 2416
Signed informed consent
form missing
1 < 01 Investigator: 110%
Withdrawal 17 07
Not eligible (i.e.
inclusion/exclusion)
61 25
Major protocol violation 29 12
Measurement not acquired 60 25
Coveragea 98 41
Ineligible histopathology
(preparation quality)
8 03 Pathology: 41%
Missing histopathologyb 39 16
Inaccurate mapping of
histopathologyc
7 03
No consensusd 44 18
Poor reference qualitye 95 39 Device-related: 45%
Device failure 14 06
Eligible lesions 1943
aLess than 75% of the lesion was covered with measurements,
e.g. a 10 9 10-mm2 lesion only measured once was excluded.
bNo histology slides were/could be provided by the site.
cProvided histology slides were not mapped accurately to the
lesion measured. dThe consensus board could not agree on a
final diagnosis. eInability to obtain a reference measurement with
adequate quality after four consecutive attempts.
Table 4 Observed sensitivity (Sens) and specificity (Spec) for Nevisense
combined with lower (LCB) and upper 95% confidence bounds (UCB),
and true and false positives/negatives in the efficacy analysis population
differentiated by histopathological lesion type and melanoma thickness
Type Sens TPa FNa Total LCBb UCBb
Melanomac 966 256 9 265 937d 984
pTis 938 105 7 112 876 975
pT1a 979 92 2 94 925 997
pT1b 100 19 0 19 824 100
pT2a 100 24 0 24 858 100
pT2b 100 11 0 11 715 100
pT3a 100 1 0 1 25 100
pT3b 100 3 0 3 292 100
pT4a 100 1 0 1 25 100
pT4b NA 0 0 0 NA NA
Severe dysplasiae 841 132 25 157 774 894
Type Spec TNa FPa Total LCBb UCBb
Mild/moderate dysplasia 361 357 631 988 331 392
Moderate dysplasia 241 80 252 332 196 291
Mild dysplasia 413 212 301 513 370 457
Dysplastic Lentigo 400 2 3 5 53 853
Structural disorder
only
733 11 4 15 449 922
Undecidedf 423 52 71 123 334 515
Melanocytic naevus 367 131 226 357 317 419
Blue naevus 240 6 19 25 94 451
Compound naevus 340 33 64 97 247 443
Dermal naevus 385 37 59 96 288 490
Halo naevus 429 3 4 7 99 816
Junction naevus 857 6 1 7 421 996
Lentigo 550 11 9 20 315 769
Other 333 9 18 27 165 540
Reed naevus 313 5 11 16 110 587
Spitz naevus 0 0 5 5 0 522
Undecided 368 21 36 57 245 507
Other 116 13 99 112 63 190
Lichenoid keratosis 0 0 4 4 0 602
Seborrhoeic keratosis 78 4 47 51 22 189
Other 158 9 48 57 75 279
Overall specificity 344 501 956 1457 320 369
Type Sens TPa FNa Total LCBb UCBb
NMSC 100 55 0 55 935 100
BCC 100 48 0 48 926 100
SCC 100 7 0 7 590 100
SCC in situ 100 6 0 6 541 100
SCC invasive 100 1 0 1 25 100
Actinic keratosis 875 7 1 8 474 997
Merkel cell carinoma 100 1 0 1 25 100
TP, true positive; TN, true negative; FP, false positive; FN, false
negative; NA, not applicable; NMSC, nonmelanoma skin cancer;
BCC, basal cell carcinoma; SCC, squamous cell carcinoma. aTP
correctly identified as positive, FN incorrectly identified as nega-
tive, TN correctly identified as negative and FP incorrectly identi-
fied as positive by the investigational device. bExact LCB and
UCB calculated using the Clopper–Pearson method. cAmerican
Joint Committee on Cancer staging system for melanoma sixth
edition was used with ad hoc adoption of the seventh edition dur-
ing the course of the study when pronounced mitosis was pres-
ent.2,58 dExact Clopper–Pearson and mid-P one-sided 95% LCB
estimated at 942% and 944%, respectively. eSevere cytological
atypia or architectural disorder where diagnosed as severe dys-
plasia. fNo majority board agreement on degree of dysplasia.
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quality to enable a classification according to the ABCD rule,
ABCD dermoscopy rule and the seven-point checklist.
The result of the dermoscopic and investigational site’s his-
topathological evaluations in conjunction with the Nevisense
are presented in Table 5, and grouped according to the
study’s HGS.
The observed sensitivity with the ABCD dermoscopy rules
for melanoma detection with a cut-off of 475 and 545 was
542% and 471%, with an observed specificity of 901% and
94%, respectively.
The observed sensitivity for melanoma detection with the
original and weighted seven-point checklists was 492% and
609% with an observed specificity of 942% and 892%,
respectively.
The observed sensitivity for the reviewing dermatologist,
when considering the combined features for malignancy
(overall visual board malignancy grading), was 706%, with
an observed specificity of 814%.
Performance of the investigational site’s
histopathologists
The observed sensitivity and specificity for melanoma of the
investigational site’s histopathologists was 849% (225/265)
and 981% (1429/1457), respectively. The observed sensitiv-
ity increased with melanoma thickness, from 732% for Tis to
100% for T2b–T4.
Safety
A total of 36 adverse events (AEs) were observed in 28
patients (15%), out of which only three AEs that occurred on
three patients (02%) were defined as definitely related to the
device. All AEs related to the device were of mild severity. No
serious AEs, serious adverse device effects or unanticipated
adverse device effects were observed throughout the entire
study.
Discussion
Melanoma detection often poses a challenge in equivocal
lesions or in patients with many atypical naevi. Therefore, a
component of the clinical work-up and interpretation incorpo-
rates not only lesion-specific information, but also patient-
derived melanoma risk factors, which includes a comparative
analysis of all lesions present on a patient.53–56 Even if the
clinical decision is based on a collective interpretation of all
the presently available clinical risk factors, melanomas can still
be misdiagnosed as benign lesions.37 As early detection of
melanoma is vital for treatment outcome and survival,1,2
Table 5 Observed sensitivity and specificity for the dermoscopic, investigational site’s histopathology evaluations, as well as the Nevisense result
grouped according to the study’s histopathological gold standard (HGS). The results are derived from the cohort of eligible and evaluable lesions
that had sufficient image quality to render a dermoscopic evaluation
Type Seven-point
Seven-point
weighted
ABCD
dermoscopy < 545
ABCD
dermoscopy < 475
Malignancy
gradinga
Investigational
site’s
histopathology Nevisense
Melanoma sensitivity 492 609 471 542 706 845 971
pTis 287 436 287 376 554 733 941
pT1a 571 655 512 571 750 893 988
pT1b 765 765 765 824 882 1000 1000
pT2a 636 864 727 727 909 955 1000
pT2b 889 1000 889 889 1000 1000 1000
pT3a 1000 1000 1000 1000 1000 1000 1000
pT3b 1000 1000 667 1000 1000 1000 1000
pT4a 1000 1000 0 1000 1000 1000 1000
Severe dysplasia
sensitivityb
121 248 128 208 383 NA 839
Overall specificity 942 892 940 901 814 980 358
All values given as a percentage. NA, not applicable. aOverall malignancy grading as determined by the visual classification board with a fixed
cut-off at 4. bSevere cytologic atypia or architectural disorder where diagnosed as severe dysplasia.
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Fig 1. The study’s histopathological gold standard plotted against the
Nevisense score outcome. EIS, electrical impedance spectroscopy.
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additional objective information that could assist in the early
detection of melanoma could significantly reduce the morbid-
ity related to the unnecessary removal of benign lesions and
has the potential to improve mortality through early diagno-
sis.
In this study, a postexcision evaluation of the isolated per-
formance of dermoscopy was conducted according to three
dermoscopic classification algorithms in which the evaluator
was presented with the clinical and dermoscopic images of all
excised lesions from a patient. The results show that a consid-
erable amount of the included melanomas were equivocal
lesions with insufficient dermoscopic criteria to be classified as
malignant.
There are several plausible explanations for the relatively
low sensitivity (471–706%) observed in the postexcisional
dermoscopic evaluation with limited clinical data. Firstly, the
evaluation was conducted on a cohort of 850% in situ and
early invasive melanomas. In addition, the evaluations were
completed by dermatologists with 2–5 years of experience in
dermoscopy, with additional support in difficult cases. Most
importantly, the evaluators did not have the added benefit of
comparative analysis of all lesions present on the patients, i.e.
they could only base their judgement on the excised lesions.
While the outcome of the dermoscopy assessment might
have been different if the lesions had been evaluated by more
experienced dermoscopists, the results of the study likely
reflect the dermoscopic acumen of an average dermatologist.
It has to be stressed that almost all lesions were removed
owing to some clinical concern for melanoma, as it would
not be ethical to excise lesions deemed benign clinically,
except for functional or cosmetic reasons. As mostly preselect-
ed equivocal lesions destined for excision were included in
the study, the dermoscopic diagnostic performance is not a
true reflection of the performance in normal clinical practice.
However, it gives an insight into the isolated performance of
dermoscopy on equivocal lesions submitted for biopsy, which
is the intended use of Nevisense.
Nevisense was able to achieve a high sensitivity (966%) in
a melanoma cohort consisting mostly of in situ and early inva-
sive melanoma without fully compromising the specificity
(344%). The observed sensitivity of the device increased with
Breslow thickness, and no invasive melanoma at stages T1b–
T4 were missed by the device. Cases where the investigational
device gave a false negative reading occurred mostly in small
lesions with few or no dermoscopic features, and with low
cellularity.
Two early-stage invasive melanomas were inaccurately clas-
sified as negative, but in both cases compliance with the mea-
surement procedure could not be fully verified. In fact, for
one lesion the verification data were missing, and the other
lesion had not been fully covered with measurements. As the
system only detects changes that occur directly underneath the
electrode, it is important that the lesions are measured com-
pletely and/or that the most suspicious malignant part of the
lesion is measured to ensure as accurate a reading as possible.
A review of the 98 lesions excluded owing to coverage issues
included a total of 22 melanomas, of which the device still
accurately classified 20 as positive. These are good results, as
for some cases only 250% of the surface had been measured
with the device, suggesting that even though coverage is
important, it is not vital in most cases.
The overall observed specificity was 344%. Approximately
one-third of the equivocal lesions submitted for biopsy in the
study were accurately identified as negative by the device and
thus would not have needed a biopsy. Furthermore, the high
observed NPV of 982% – equal to that of the observed NPV
of histology in the study – ensures that few melanomas will
be inaccurately left untreated when given a low score by the
device.
There are two additional results that are important to high-
light. Firstly, a high proportion of seborrhoeic keratoses were
inaccurately classified as positive. The high ratio of positive
readings was anticipated as this has been observed in previous
studies, mainly owing to the typically high degree of struc-
tural changes compared with normal skin. However, the sys-
tem is intended to be used by dermatologists or clinicians
trained in the diagnosis of skin cancer who will almost always
recognize seborrhoeic keratoses clinically and would therefore
seldom apply Nevisense to these lesions. Secondly, the
observed sensitivity of 1000% in NMSC is extremely valuable
as these malignancies should not be left untreated. Few other
noninvasive technologies are able to identify accurately NMSC,
as well as melanoma.
The observed sensitivity and specificity presented do not
take into account the clinical information regarding the full
extent of the patient’s history, as well as the comparative
analysis with other lesions, which has been shown to be criti-
cal in the clinical decision of whether to excise a lesion or
not. However, in reality, clinicians often end up performing
single lesion examinations owing to factors such as time con-
straints; as such, the isolated performance of the dermoscopy
evaluation would reflect their diagnostic accuracy.57 As can be
discerned from Table 5, a large number of melanomas
included in the study were equivocal lesions and hard to dif-
ferentiate from nonmalignant equivocal lesions.
The Nevisense system is intended for use on cutaneous
lesions with one or more clinical or historical characteristics
of melanoma. The system is designed to be used when a clini-
cian chooses to obtain additional information when consider-
ing excision and is not meant to be used to confirm a clinical
diagnosis of melanoma. It should be used by physicians
trained in the clinical diagnosis of skin cancer to ensure the
system result is one element of the overall clinical assessment.
Not only should the negative or positive EIS outcome be
incorporated into the assessment, but also the EIS score, as it
is coupled with the stage and severity of a lesion.
In summary, Nevisense has been shown to be an accurate
and safe device that should be used in conjunction with the
clinical risk assessment for patients with suspicion of melanoma
in the intended use population. A negative or positive EIS read-
ing in combination with the score outcome should be used as
guidance for whether a lesion should be excised or not.
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